CRISPR Therapeutics AG (CRSP) Return on Sales (2016 - 2026)
CRISPR Therapeutics AG (CRSP) posted Return on Sales of 0.84% for Q1 2026, up 55.1% sequentially from 1.88% in Q4 2025, and up 73.0% YoY from 0.49% in Q1 2025.
CRISPR Therapeutics AG (CRSP) Return on Sales (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Return on Sales for 11 years, with the latest figure at 0.84% in Q1 2026.
- Quarterly Return on Sales rose 73.0% year-over-year to 0.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.46% (down 147.0% YoY) and the FY2025 annual result came in at 1.75%, down 176.0% from the prior year.
- Return on Sales improved to 0.84% in Q1 2026 per CRSP's latest filing, from 1.88% in the prior quarter.
- Over five years, Return on Sales peaked at 0.1% in Q4 2024 and troughed at 184.29% in Q4 2022.
- A 5-year average of 13.56% and a median of 1.57% in 2025 frame the typical range for Return on Sales.
- The sharpest annual moves came in 2022 and 2023: Return on Sales sank 18418 bps in 2022, then jumped 18430 bps in 2023.
- Over 5 years, Return on Sales stood at 184.29% in 2022, then soared by 100 bps to 0.0% in 2023, then soared by 2212 bps to 0.1% in 2024, then tumbled by 1928 bps to 1.88% in 2025, then surged by 55 bps to 0.84% in 2026.
- According to Business Quant data, Return on Sales over the past three periods registered 0.84%, 1.88%, and 1.2% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 0.00% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.00% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.00% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.00% |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -0.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.09% |
| Mar 31, 2026 | -0.84% |
| Dec 31, 2025 | -1.88% |
| Sep 30, 2025 | -1.20% |
| Jun 30, 2025 | -2.34% |
| Mar 31, 2025 | -1.57% |
| Dec 31, 2024 | 0.10% |
| Sep 30, 2024 | -1.43% |
| Jun 30, 2024 | -2.45% |
| Mar 31, 2024 | -2.31% |
| Dec 31, 2023 | 0.00% |
| Sep 30, 2023 | -0.02% |
| Jun 30, 2023 | -0.01% |
| Mar 31, 2023 | -0.01% |
| Dec 31, 2022 | -184.29% |
| Sep 30, 2022 | -18.57% |
| Jun 30, 2022 | -11.76% |
| Mar 31, 2022 | -1.91% |
| Dec 31, 2021 | -0.11% |
| Sep 30, 2021 | -1.54% |